When the ADA determines that a particular TR is futile, it is probably in the patients' best interest to transition them to a new, presumably superior TR. Once the possibility of treatment transition is accepted, there are numerous interesting implications for decision making and analysis. The TR to which they should move ought most likely be controlled by the same adaptive randomization algorithm used in preliminary intake, but, of course, informed by the new background that this patient has previously been under another TR; that is, the simplest thing to do is to treat this patient as through they are presenting for the fist time, although with newly expanded historical information. One theoretical question is: Should an adjustment be made to the forward-going statistical information generated by this patient to account for biases introduced by the patient having been already guided by the ADA previously? This interacts with the problem of complex treatment dynamics, esp. regarding sequential treatments, discussed in more detail below. In computing the transition choices for this patient, there may be evidence regarding specific changes in regimen, for example because a patient was not able to handle a particular treatment, and so there may be some evidence already regarding this specific transition. Regardless, such transitions offer us both additional data for the new TR to which they transition, as well as additional data regarding patients having been transitioned from the futile TR to new ones. It may be advisable to make such transitions in an incremental manner, for example, transitioning a handful of patients to a number of alternative TRs and observing their performance, and then resorting them as evidence accrues regarding these transitions.
